WhaleCreep

Casdin Capital, LLC 13F holdings, Q2 2017

Hedge fundSEC filingsCompare with another fundHoldings as of 2017-06-30, filed 2017-08-14

Casdin Capital, LLC disclosed 31 US equity positions worth $250.0m in its Q2 2017 13F filing. Its largest position is LOXO ONCOLOGY INC at 11.5% of the reported book, followed by SG7 and FOUNDATION MEDICINE INC. Versus Q1 2017 it opened 5 new positions, added to 16, reduced 3 and exited 3.

$250m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
31
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
11.5%
Largest position
The largest single position as a share of the reported equity book.
61.0%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
19
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2017: 5 new, 16 added, 3 reduced, 3 exited

31 rows
LOXO ONCOLOGY INC no ticker–11.5%$28.9m360,0000.0%held
SG7 SAGE THERAPEUTICS INC–8.1%$20.3m255,0000.0%held
FOUNDATION MEDICINE INC no ticker–7.6%$19.1m480,0000.0%held
2655787D BLUEPRINT MEDICINES CORP–5.6%$13.9m275,000−6.6%reduced
EVH EVOLENT HEALTH INCHealthcare5.3%$13.2m520,0000.0%held
AGIO AGIOS PHARMACEUTICALS INCHealthcare5.2%$13.1m255,000+7.4%added
SGMOQ SANGAMO THERAPEUTICS INCHealthcare4.9%$12.3m1.40m+65%added
CLVSEUR CLOVIS ONCOLOGY INC–4.9%$12.2m130,000+465%added
ONCEEUR SPARK THERAPEUTICS INC–4.1%$10.2m170,000+26%added
KITE PHARMA INC no ticker–3.7%$9.3m90,000+112%added
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare3.3%$8.4m105,000+91%added
GNMK GENMARK DIAGNOSTICS INC–3.2%$8.1m685,000+71%added
EPZMEUR EPIZYME INC–3.1%$7.9m520,000+7.2%added
BOLDEUR AUDENTES THERAPEUTICS INC–3.1%$7.7m400,000+54%added
BLUEBIRD BIO INC no ticker–2.7%$6.8m65,000+155%added
T8S TESARO INC–2.7%$6.7m48,000+174%added
VYGR VOYAGER THERAPEUTICS INCHealthcare2.7%$6.6m740,000+48%added
CDXS CODEXIS INCHealthcare2.6%$6.5m1.19m+76%added
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–2.4%$5.9m215,000+112%added
ILMN ILLUMINA INCHealthcare2.2%$5.5m31,500–new
GILD GILEAD SCIENCES INCHealthcare2.1%$5.3m75,000–new
MYOKEUR MYOKARDIA INC–2.1%$5.2m395,000+49%added
SYRSEUR SYROS PHARMACEUTICALS INC–1.2%$2.9m182,1410.0%held
CTMX CYTOMX THERAPEUTICS INC.Healthcare1.1%$2.8m177,5000.0%held
OVID OVID THERAPEUTICS INCHealthcare0.9%$2.3m221,700–new
JNCEEUR JOUNCE THERAPEUTICS INC–0.9%$2.2m160,000+23%added
EDIT EDITAS MEDICINE INCHealthcare0.9%$2.2m133,3330.0%held
FATE FATE THERAPEUTICS INCHealthcare0.7%$1.8m550,000–new
AMRSEUR AMYRIS INC–0.6%$1.6m500,000–new
PACB PACIFIC BIOSCIENCES CALIF INHealthcare0.4%$1.1m300,000−57%reduced
CRIS CURIS INC–0.06%$161k85,000−63%reduced

Exited since Q1 2017

3 rows
MDRX VERADIGM INC2.3%$3.9m
AMYRIS INC no ticker1.9%$3.2m
ADVMCHF ADVERUM BIOTECHNOLOGIES INC0.7%$1.1m

Sector mix

  • Unclassified67.6%
  • Healthcare32.4%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters